Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker PMN
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | SCHEDULE 13G | PMN ProMIS Neurosciences Inc. | Phillip Gross | 703,550 | 7.7% | SCHEDULE 13G ↗ |
| Nov 12, 2026 | SCHEDULE 13G | PMN ProMIS Neurosciences Inc. | Robert Atchinson | 703,550 | 7.7% | SCHEDULE 13G ↗ |
| Nov 12, 2026 | SCHEDULE 13G | PMN ProMIS Neurosciences Inc. | Adage Capital Management, L.P. | 703,550 | 7.7% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | PMN ProMIS Neurosciences Inc. | Ms. Lillian Nordahl | 736,881 | 7.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | PMN ProMIS Neurosciences Inc. | Dr. Jeffrey R. Jay, M.D. | 736,881 | 7.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | PMN ProMIS Neurosciences Inc. | Great Point Partners, LLC | 736,881 | 7.7% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PMN ProMIS Neurosciences Inc. | Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. | 696,378 | 7.8% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PMN ProMIS Neurosciences Inc. | Wellington Management Company LLP | 696,378 | 7.8% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PMN ProMIS Neurosciences Inc. | Wellington Investment Advisors Holdings LLP | 696,378 | 7.8% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PMN ProMIS Neurosciences Inc. | Wellington Group Holdings LLP | 696,378 | 7.8% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PMN ProMIS Neurosciences Inc. | Wellington Management Group LLP | 696,378 | 7.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G | PMN ProMIS Neurosciences Inc. | Ms. Lillian Nordahl | 954,082 | 10.0% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | PMN ProMIS Neurosciences Inc. | Dr. Jeffrey R. Jay, M.D. | 954,082 | 10.0% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | PMN ProMIS Neurosciences Inc. | Great Point Partners, LLC | 954,082 | 10.0% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | PMN ProMIS Neurosciences Inc. | Wellington Management Company LLP | 895,871 | 10.0% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | PMN ProMIS Neurosciences Inc. | Wellington Investment Advisors Holdings LLP | 895,871 | 10.0% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | PMN ProMIS Neurosciences Inc. | Wellington Group Holdings LLP | 895,871 | 10.0% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | PMN ProMIS Neurosciences Inc. | Wellington Management Group LLP | 895,871 | 10.0% | SCHEDULE 13G ↗ |
| May 7, 2026 | SCHEDULE 13G/A (amended) | PMN ProMIS Neurosciences Inc. | Title 19 Promis | 181,632 | 2.0% | SCHEDULE 13G/A ↗ |
| May 7, 2026 | SCHEDULE 13G/A (amended) | PMN ProMIS Neurosciences Inc. | Michael S. Gordon | 181,632 | 2.0% | SCHEDULE 13G/A ↗ |
| Apr 7, 2026 | SCHEDULE 13G | PMN ProMIS Neurosciences Inc. | Janus Henderson Group PLC | 1.29M | 14.4% | SCHEDULE 13G ↗ |
| Mar 18, 2026 | SCHEDULE 13G | PMN ProMIS Neurosciences Inc. | Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. | 895,877 | 10.0% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PMN ProMIS Neurosciences Inc. | Steven Boyd | 504,673 | 0.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PMN ProMIS Neurosciences Inc. | Armistice Capital, LLC | 504,673 | 0.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PMN ProMIS Neurosciences Inc. | Ms. Lillian Nordahl | 409,648 | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PMN ProMIS Neurosciences Inc. | Dr. Jeffrey R. Jay, M.D. | 409,648 | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PMN ProMIS Neurosciences Inc. | Great Point Partners, LLC | 409,648 | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 10, 2026 | SCHEDULE 13G | PMN ProMIS Neurosciences Inc. | Ortav Yehudai | 933,477 | 9.9% | SCHEDULE 13G ↗ |
| Feb 10, 2026 | SCHEDULE 13G | PMN ProMIS Neurosciences Inc. | Trails Edge Biotechnology Master Fund, LP | 933,477 | 9.9% | SCHEDULE 13G ↗ |
| Feb 10, 2026 | SCHEDULE 13G | PMN ProMIS Neurosciences Inc. | Trails Edge Capital Partners, LP | 933,477 | 9.9% | SCHEDULE 13G ↗ |
| Feb 6, 2026 | SCHEDULE 13G | PMN ProMIS Neurosciences Inc. | Deep Track Special Opportunities Fund, LP. | 199,104 | 2.2% | SCHEDULE 13G ↗ |
| Feb 6, 2026 | SCHEDULE 13G | PMN ProMIS Neurosciences Inc. | David Kroin | 902,561 | 10.0% | SCHEDULE 13G ↗ |
| Feb 6, 2026 | SCHEDULE 13G | PMN ProMIS Neurosciences Inc. | Deep Track Biotechnology Master Fund, Ltd. | 703,457 | 7.8% | SCHEDULE 13G ↗ |
| Feb 6, 2026 | SCHEDULE 13G | PMN ProMIS Neurosciences Inc. | Deep Track Capital, LP | 902,561 | 10.0% | SCHEDULE 13G ↗ |
| Feb 5, 2026 | SCHEDULE 13D/A (amended) | PMN ProMIS Neurosciences Inc. | Fan Yu | 1.64M | 17.0% | SCHEDULE 13D/A ↗ |
| Feb 5, 2026 | SCHEDULE 13D/A (amended) | PMN ProMIS Neurosciences Inc. | ABG V-SIV X Limited | 412,200 | 4.5% | SCHEDULE 13D/A ↗ |
| Feb 5, 2026 | SCHEDULE 13D/A (amended) | PMN ProMIS Neurosciences Inc. | ABG Global Life Science Capital Partners V GP Limited | 659,520 | 7.1% | SCHEDULE 13D/A ↗ |
| Feb 5, 2026 | SCHEDULE 13D/A (amended) | PMN ProMIS Neurosciences Inc. | ABG Global Life Science Capital Partners V GP, L.P. | 659,520 | 7.1% | SCHEDULE 13D/A ↗ |
| Feb 5, 2026 | SCHEDULE 13D/A (amended) | PMN ProMIS Neurosciences Inc. | Ally Bridge Group Global Life Science Capital Partners V, L.P. | 659,520 | 7.1% | SCHEDULE 13D/A ↗ |
| Feb 5, 2026 | SCHEDULE 13D/A (amended) | PMN ProMIS Neurosciences Inc. | ABG V-SIV IX Limited | 659,520 | 7.1% | SCHEDULE 13D/A ↗ |
| Feb 5, 2026 | SCHEDULE 13D/A (amended) | PMN ProMIS Neurosciences Inc. | Ally Bridge MedAlpha Master Fund L.P. | 572,677 | 6.3% | SCHEDULE 13D/A ↗ |
| Feb 5, 2026 | SCHEDULE 13D/A (amended) | PMN ProMIS Neurosciences Inc. | Ally Bridge Group (NY) LLC | 572,677 | 6.3% | SCHEDULE 13D/A ↗ |
| Feb 5, 2026 | SCHEDULE 13D/A (amended) | PMN ProMIS Neurosciences Inc. | ABG Management Ltd. | 572,677 | 6.3% | SCHEDULE 13D/A ↗ |
| Feb 5, 2026 | SCHEDULE 13G/A (amended) | PMN ProMIS Neurosciences Inc. | Sphera Global Healthcare Management LP. | 180,698 | 7.8% | SCHEDULE 13G/A ↗ |
| Feb 5, 2026 | SCHEDULE 13G/A (amended) | PMN ProMIS Neurosciences Inc. | Sphera Global Healthcare GP Ltd. | 180,698 | 7.8% | SCHEDULE 13G/A ↗ |
| Feb 5, 2026 | SCHEDULE 13G/A (amended) | PMN ProMIS Neurosciences Inc. | Sphera Funds Management Ltd. | 180,698 | 7.8% | SCHEDULE 13G/A ↗ |
| Feb 2, 2026 | SCHEDULE 13D/A (amended) | PMN ProMIS Neurosciences Inc. | Fan Yu | 6.07M | 11.3% | SCHEDULE 13D/A ↗ |
| Feb 2, 2026 | SCHEDULE 13D/A (amended) | PMN ProMIS Neurosciences Inc. | Ally Bridge MedAlpha Master Fund L.P. | 6.07M | 11.3% | SCHEDULE 13D/A ↗ |
| Feb 2, 2026 | SCHEDULE 13D/A (amended) | PMN ProMIS Neurosciences Inc. | Ally Bridge Group (NY) LLC | 6.07M | 11.3% | SCHEDULE 13D/A ↗ |
| Feb 2, 2026 | SCHEDULE 13D/A (amended) | PMN ProMIS Neurosciences Inc. | ABG Management Ltd. | 6.07M | 11.3% | SCHEDULE 13D/A ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 7:02 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances